31.01
price up icon0.72%   0.4103
 
loading
Precedente Chiudi:
$30.60
Aprire:
$31.08
Volume 24 ore:
631.52K
Relative Volume:
0.67
Capitalizzazione di mercato:
$2.43B
Reddito:
$399.58M
Utile/perdita netta:
$-54.04M
Rapporto P/E:
-41.35
EPS:
-0.75
Flusso di cassa netto:
$40.13M
1 W Prestazione:
-2.96%
1M Prestazione:
-3.14%
6M Prestazione:
-5.46%
1 anno Prestazione:
+55.26%
Intervallo 1D:
Value
$30.64
$31.97
Intervallo di 1 settimana:
Value
$30.18
$31.97
Portata 52W:
Value
$19.09
$47.32

Veracyte Inc Stock (VCYT) Company Profile

Name
Nome
Veracyte Inc
Name
Telefono
(650) 243-6300
Name
Indirizzo
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
Dipendente
824
Name
Cinguettio
@veracyte
Name
Prossima data di guadagno
2025-02-24
Name
Ultimi documenti SEC
Name
VCYT's Discussions on Twitter

Confronta VCYT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Diagnostics & Research icon
VCYT
Veracyte Inc
31.04 2.43B 399.58M -54.04M 40.13M -0.75
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
431.62 166.47B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
192.84 135.88B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
420.52 32.74B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
102.58 29.40B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
143.05 26.30B 15.41B 1.37B 2.11B 7.50

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-20 Iniziato Craig Hallum Buy
2024-12-05 Downgrade Goldman Buy → Neutral
2024-11-15 Iniziato Wolfe Research Outperform
2024-10-16 Iniziato UBS Buy
2024-10-10 Iniziato Guggenheim Buy
2024-02-23 Reiterato Needham Buy
2023-01-18 Downgrade Raymond James Outperform → Mkt Perform
2023-01-05 Iniziato Scotiabank Sector Outperform
2022-01-07 Iniziato Stephens Overweight
2021-11-18 Ripresa Goldman Buy
2021-06-15 Iniziato Raymond James Outperform
2021-02-18 Ripresa Needham Buy
2021-01-28 Iniziato Truist Buy
2020-11-10 Iniziato KeyBanc Capital Markets Sector Weight
2020-09-09 Iniziato Morgan Stanley Underweight
2019-07-31 Iniziato Lake Street Buy
2019-07-02 Iniziato Needham Buy
2018-11-29 Downgrade Janney Buy → Neutral
2018-10-31 Aggiornamento Janney Neutral → Buy
2017-11-07 Downgrade Janney Buy → Neutral
2017-11-07 Downgrade Piper Jaffray Overweight → Neutral
2017-08-31 Ripresa BTIG Research Buy
2016-11-14 Ripresa Leerink Partners Outperform
2015-12-18 Iniziato Cantor Fitzgerald Buy
2015-06-11 Reiterato Leerink Partners Outperform
2013-11-26 Iniziato William Blair Outperform
Mostra tutto

Veracyte Inc Borsa (VCYT) Ultime notizie

pulisher
09:25 AM

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting | VCYT Stock News - GuruFocus

09:25 AM
pulisher
09:00 AM

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting - Business Wire

09:00 AM
pulisher
Apr 21, 2025

Veracyte data joins NCI SEER database for research By Investing.com - Investing.com South Africa

Apr 21, 2025
pulisher
Apr 21, 2025

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release | VCYT Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release - Business Wire

Apr 21, 2025
pulisher
Apr 18, 2025

Should You Continue to Hold Veracyte Stock in Your Portfolio? - MSN

Apr 18, 2025
pulisher
Apr 16, 2025

Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 - 01net

Apr 16, 2025
pulisher
Apr 16, 2025

Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 | VCYT Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Cancer Diagnostics Leader Veracyte Announces Q1 2025 Earnings Date: Key Updates Coming May 7 - Stock Titan

Apr 16, 2025
pulisher
Apr 15, 2025

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Apr 15, 2025
pulisher
Apr 14, 2025

Here's Why Veracyte (VCYT) is a Strong Growth Stock - Yahoo Finance

Apr 14, 2025
pulisher
Apr 10, 2025

Veracyte And 2 More Stocks That Might Be Trading Below Their Estimated Value - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

Veracyte (VCYT) Just Overtook the 20-Day Moving Average - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength? - Nasdaq

Apr 10, 2025
pulisher
Apr 09, 2025

Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating - Investing.com Australia

Apr 09, 2025
pulisher
Apr 08, 2025

Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.

Apr 08, 2025
pulisher
Apr 07, 2025

Veracyte Scores Relative Strength Rating Upgrade; Hits Key Threshold - MSN

Apr 07, 2025
pulisher
Mar 28, 2025

Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever! - Insider Monkey

Mar 28, 2025
pulisher
Mar 26, 2025

9 AI News and Ratings on Investors’ Radar - Insider Monkey

Mar 26, 2025
pulisher
Mar 26, 2025

Craig-Hallum bullish on Veracyte, initiates with a Buy - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade - Yahoo

Mar 26, 2025
pulisher
Mar 26, 2025

New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - 01net

Mar 26, 2025
pulisher
Mar 25, 2025

Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

Veracyte (VCYT) Shares Cross Above 200 DMA - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Veracyte says new data demonstrate accuracy of WGS-based platform - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

New Data Demonstrate Accuracy Of Veracyte's Whole-Genome Sequencing-Based Mrd Testing Platform For Muscle-Invasive Bladder Cancer - Marketscreener.com

Mar 25, 2025
pulisher
Mar 20, 2025

5 Analysts Assess Veracyte: What You Need To Know - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Craig-Hallum initiates Veracyte stock with Buy, sets $45 target By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Craig-Hallum initiates Veracyte stock with Buy, sets $45 target - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Craig-Hallum Initiates Veracyte at Buy With $45 Price Target -March 20, 2025 at 07:28 am EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 - BioSpace

Mar 20, 2025
pulisher
Mar 19, 2025

Veracyte's Decipher, MRD tests highlights to be presented at EAU25 -March 19, 2025 at 05:05 pm EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Veracyte's Cancer Detection Tests Prove Powerful in Major Clinical StudiesNew Product Coming - StockTitan

Mar 19, 2025
pulisher
Mar 13, 2025

Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally? - Yahoo Finance

Mar 13, 2025
pulisher
Mar 12, 2025

Analyst Sees Bottom For Myriad Genetics Stock, Issues UpgradeMyriad Genetics (NASDAQ:MYGN) - Benzinga

Mar 12, 2025
pulisher
Mar 11, 2025

Veracyte’s chief commercial officer John Leite sells $234,629 in stock By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 10, 2025

Veracyte’s chief commercial officer John Leite sells $234,629 in stock - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Veracyte (VCYT) Surged on Reporting Strong Earnings - Insider Monkey

Mar 10, 2025

Veracyte Inc Azioni (VCYT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
diagnostics_research DGX
$172.56
price up icon 4.80%
diagnostics_research WAT
$321.00
price up icon 1.26%
diagnostics_research LH
$217.63
price up icon 2.63%
$144.67
price up icon 2.80%
diagnostics_research MTD
$988.31
price up icon 1.77%
diagnostics_research IQV
$139.48
price down icon 1.42%
Capitalizzazione:     |  Volume (24 ore):